Novavax Reports Results of ResVax in P-III PREPARE Trial for Prevention of RSV Disease in Infants via Maternal Immunization

 Novavax Reports Results of ResVax in P-III PREPARE Trial for Prevention of RSV Disease in Infants via Maternal Immunization

Novavax Reports Results of ResVax in P-III PREPARE Trial for Prevention of RSV Disease in Infants via Maternal Immunization

Shots:

  • The P-III PREPARE study involves assessing ResVax vs PBO in 4,636 pregnant women to prevent the risk of RSV Disease in infants
  • PREPARE study results: didn’t met 1EPs @prevention of medically significant RSV LRTI; 39% against medically significant RSV LRTI; 44% against RSV LRTI hospitalizations; 48% against RSV LRTI with severe hypoxemia; reduction in LRTI  hospitalizations & hypoxemia (25% & 39%); vaccine efficacy against RSV LRTI hospitalization & hypoxemia@< 33wks. pregnancy (53%,70% vs 26%,44%)
  • ResVax is an RSV fusion (F) protein recombinant nanoparticle vaccine used in combination with aluminum phosphate for prevention of severe LRTI in infants >1yrs.

Click here to read full press release/ article | Ref: Novavax | Image: Getty images

Shiwani Sharma

Shiwani Sharma was Senior Editor at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post